Anjali Y. Hari, MD, speaks to the rationale for examining hyperthermic intraperitoneal chemotherapy in a population of frail and non-frail patients with ovarian cancer.
Anjali Hari, MD
Advertisement
Articles by Anjali Hari, MD
Anjali Hari, MD, Speaks to Survival/Safety Outcomes With HIPEC in Frail and Non-Frail Ovarian Cancer
Anjali Hari, MD, discusses survival and safety outcomes with hyperthermic intraperitoneal chemotherapy in frail and non-frail patients with ovarian cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA OKs Subcutaneous Daratumumab in High-Risk Smoldering Multiple Myeloma
2
How ADCs are Replacing Chemotherapy as Breast Cancer Treatment
3
How Will the Continued Success of ADCs in Breast Cancer Be Propelled in the Future?
4
Neoadjuvant Nivolumab/Ipilimumab Shows Superior EFS in Resectable Melanoma
5
